| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2025―Nov―21 |
Risk Factors of Chronic Spontaneous Urticaria with COVID-19 Vaccination: A Cross-Sectional Study |
Hossein Esmaeilzadeh, Mohammad Amin Gholami, Negar Mortazavi, Mohammad Reza Yousefi, Mohebat Vali |
| 2 |
[GO] |
2025―Mrz―22 |
Evaluating the Role of the Renin-angiotensin System in COVID-19: Implications for ACE Inhibitor and ARB Use During SARS-CoV-2 Infection |
Sarah Renee Tritsch, Evelyn Mendoza-Torres, Mónica Gómez-Pulido, Jairo Castellar-López, Rebecca Lynch, Carlos Andres Herrera Gomez, et al. (+8) Hana Akselrod, Adrienne Poon, Samuel Joseph Simmens, Christopher N. Mores, Gary Leonard Simon, Lauren C. Ray, Sarah Conway, Aileen Yu-hen Chang |
| 3 |
[GO] |
2024―Dez―21 |
Epidemiology, Symptoms and Pathophysiology of Long Covid Complications |
Chongyang Zhang, Chiung-Yu Hung, Chia George Hsu |
| 4 |
[GO] |
2024―Jan―29 |
Examining the Relationship between SARS-CoV-2 Infection and Type 1 Diabetes: A Reanalysis of Recent Findings |
Yongxin Zhang, Ying Wang |
| 5 |
[GO] |
2023―Okt―03 |
Would It be Possible for a SARS-CoV-2 Infection to Affect the Male Reproductive System? |
Kaveh Rahimi, Akram Ebrahimifar, Mehri Rahimi |
| 6 |
[GO] |
2023―Mai―24 |
Is Interstitial Macrophage Mainly Responsible for Lung Injury in SARS-CoV-2 Infection? |
José Guillermo Cabanillas López |
| 7 |
[GO] |
2023―Jan―06 |
Is Omicron Variant of COVID-19 Threatening Health Like Other Variants? |
|
| 8 |
[GO] |
2022―Jan―12 |
The Return of Tocilizumab for Patients with COVID-19 Pneumonia |
|
| 9 |
[GO] |
2022―Jan―05 |
COVID-19 Clinical Outcomes and Vaccine Efficacy among Patients with Hematologic Malignancies |
|
| 10 |
[GO] |
2021―Okt―10 |
Neurological Manifestations Associated with SARS-CoV-2 Invasion of the Autonomous Nervous System |
|
| 11 |
[GO] |
2021―Sep―06 |
Efficacy of Therapeutic Plasma Exchange Alone or in Combination with Ruxolitinib for the Treatment of Penn Class 3 and 4 Cytokine Release Syndrome Complicating COVID-19 |
|
| 12 |
[GO] |
2021―Jul―06 |
The Variable Immune Response to SARS-CoV-2 Infection and Potential Treatment with Combination IL-15 and IL-21 |
|
| 13 |
[GO] |
2021―Jul―06 |
Duration of SARS-CoV-2 Infectivity |
|
| 14 |
[GO] |
2021―Jul―06 |
Increased Binding Affinity of Furin to D614G Mutant S-glycoprotein May Augment Infectivity of the Predominating SARS-CoV-2 Variant |
|
| 15 |
[GO] |
2021―Mai―04 |
Review of the COVID-19 Risk in Multiple Sclerosis |
|
| 16 |
[GO] |
2021―Mai―04 |
Structural Consequences of Variation in SARS-CoV-2 B.1.1.7 |
|
| 17 |
[GO] |
2021―Mrz―29 |
Role of BCG in Reduction of the Spread and Severity of COVID-19 |
|
| 18 |
[GO] |
2021―Mrz―29 |
COVID-19, the Immune System, and Neurological Damage |
|
| 19 |
[GO] |
2021―Mrz―29 |
A Review of the Possibility of Nafamostat Mesylate in COVID-19 Treatment |
|
| 20 |
[GO] |
2021―Mrz―29 |
Teledermatology Before, During, and After Covid-19: A Vital Tool to Improve Access and Equity in Specialty Care |
|
| 21 |
[GO] |
2021―Jan―07 |
Potentials of Interferons and Hydroxychloroquine for the Prophylaxis and Early Treatment of COVID-19 |
|
